Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study.
Quaquarini E, Sottotetti F, Agustoni F, Pozzi E, Malovini A, Teragni CM, Palumbo R, Saltalamacchia G, Tagliaferri B, Balletti E, Rinaldi P, Canino C, Pedrazzoli P, Bernardo A. Quaquarini E, et al. Among authors: sottotetti f. J Pers Med. 2022 Apr 24;12(5):679. doi: 10.3390/jpm12050679. J Pers Med. 2022. PMID: 35629102 Free PMC article.
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. Lambertini M, et al. Among authors: sottotetti f. Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28479052
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience.
Palumbo R, Sottotetti F, Quaquarini E, Gambaro A, Ferzi A, Tagliaferri B, Teragni C, Licata L, Serra F, Lapidari P, Bernardo A. Palumbo R, et al. Among authors: sottotetti f. Ther Adv Med Oncol. 2019 Jun 4;11:1758835919833864. doi: 10.1177/1758835919833864. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31210797 Free PMC article.
Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.
Tagliaferri B, Quaquarini E, Palumbo R, Balletti E, Presti D, Malovini A, Agozzino M, Teragni CM, Terzoni A, Bernardo A, Villani L, Sottotetti F. Tagliaferri B, et al. Among authors: sottotetti f. Ther Adv Med Oncol. 2020 Sep 17;12:1758835920958355. doi: 10.1177/1758835920958355. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32994808 Free PMC article.
Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study.
Palumbo R, Quaquarini E, Saltalamacchia G, Malovini A, Lapidari P, Tagliaferri B, Mollica L, Teragni CM, Barletta C, Locati LD, Sottotetti F. Palumbo R, et al. Among authors: sottotetti f. Drugs Context. 2024 Feb 5;13:2023-7-5. doi: 10.7573/dic.2023-7-5. eCollection 2024. Drugs Context. 2024. PMID: 38332945 Free PMC article.
Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
Strada MR, Palumbo R, Bernardo A, Riccardi A, Teragni C, Poggi G, Frascaroli M, Amatu A, Montagna B, Sottotetti F, Tagliaferri B, Bernardo G. Strada MR, et al. Among authors: sottotetti f. Clin Breast Cancer. 2012 Feb;12(1):30-9. doi: 10.1016/j.clbc.2011.11.001. Epub 2011 Dec 6. Clin Breast Cancer. 2012. PMID: 22154360 Clinical Trial.
44 results